SLU-PP-332

SLU-PP-332 is an experimental synthetic compound (an estrogen-related receptor agonist) studied in animals as a possible "exercise mimetic." It is not approved for human therapeutic use anywhere, and almost all evidence is preclinical.

What it is

SLU-PP-332 is a small synthetic molecule developed by academic researchers as a tool to activate a family of proteins called estrogen-related receptors (ERRα, ERRβ and ERRγ). It is sometimes labelled an "exercise mimetic" because, in laboratory animals, it switches on some of the same genetic programs that endurance exercise does. It is a research chemical, not a medicine. It has not completed human clinical trials and is not manufactured to pharmaceutical standards for therapeutic use.

How it works

Estrogen-related receptors are transcription factors — proteins that regulate which genes are turned on inside cells, particularly in muscle. By activating ERRα/β/γ, SLU-PP-332 has been shown in animal and cell studies to increase genes involved in mitochondrial biogenesis (making more cellular "powerhouses"), fatty-acid oxidation and the Krebs cycle — broadly the same pattern triggered by sustained aerobic exercise. This mechanism is established mainly in mice and cell cultures, not in humans.

What the evidence says

The evidence base is preclinical. In mouse models, SLU-PP-332 increased energy expenditure and insulin sensitivity, increased oxidative muscle fibres, raised fat oxidation, improved running endurance, and showed cardiac protection in a heart-failure model. There is also published work on detecting its metabolites for anti-doping purposes — a sign it is being used outside research settings, not that it is approved. What does not yet exist: published human clinical trials demonstrating safety or efficacy. Effects seen in mice frequently do not translate to people, and long-term human safety is unknown.

Legal & regulatory status in Australia

SLU-PP-332 is not registered on the ARTG and is not approved by the TGA for any human therapeutic use. It is an experimental research chemical. Supplying, advertising or importing such substances for human use sits outside the legitimate therapeutic-goods framework and can attract TGA enforcement action. Anyone encountering it should assume it is not lawfully available for human use in Australia and should not rely on a seller's claims.

Risks & considerations

Because there are no human trials, the human risk profile is essentially unknown — no established safe dose, no characterised side-effect list, and no data on interactions or long-term harm. ERR receptors are active in the heart, muscle and metabolic tissues, so off-target effects are plausible. Research chemicals are also frequently mislabelled, underdosed or contaminated. Using an unapproved compound can also carry sport anti-doping consequences.

What to ask a doctor

• Is there any approved, evidence-based treatment for my actual goal (metabolic health, fitness, weight)?
• Given there are no human trials, what are the realistic unknowns and dangers?
• Could this interact with my existing conditions, medications or heart health?
• What does the TGA status mean for me legally and safety-wise?
• What lifestyle or registered medical options would you recommend instead?

FAQ

Q: Is SLU-PP-332 approved as a medicine? A: No. It is not approved by the TGA or any major regulator for human therapeutic use; it remains an experimental research compound with no completed human trials. Q: Does it really replace exercise? A: No. In mice it activates some exercise-related genes, but there is no human evidence it replicates the broad benefits of physical activity. Q: Is it safe to take? A: Its safety in humans has not been established. With no clinical data, no known safe dose and possible contamination, the safest course is to discuss any interest with a registered AHPRA doctor.